Risk factor
Low price volatility
Profitability factor
Solid dividends
About
Fleury S.A., a Brazilian healthcare provider, along with its subsidiaries, delivers a broad spectrum of medical services. These offerings span diagnostics, various treatments, clinical analysis, health management, general medical care, orthopedics, and ophthalmology. The company organizes its operations into three primary segments: Diagnostic Medicine, Integrated Medicine, and Dental. Its service portfolio includes laboratory and imaging examinations, comprehensive diagnostic information, health check-ups, specialized reference laboratory functions, genomic testing, day clinic facilities, infusion centers, and dental imaging and radiology. Additionally, Fleury provides Saúde I, a digital health platform that facilitates teleconsultations, remote medical advice, online diagnostic exams, and virtual procedures. It further extends its services to corporate clients with tailored solutions, offers in-person primary care, and supports medical professionals through digital office tools and ongoing medical education. Established in 1926 and headquartered in São Paulo, Brazil, the company operates an extensive network comprising 284 outpatient service centers and 31 hospital-based units, many of which are known under brands like Labs a+, Felippe Mattoso, Lafe, Fleury, a+SP, CIP, Moacir Cunha, Vita, inlab, Weinmann, Serdil, Diagmax, IRN / CPC, Diagnosis a+, a+BA, Pretti, and Bioclinic.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/EBITDA,
Target Price
The average target price of FLRY3.SA is 20.8 and suggests 5.62% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation